Wall Street Associates’s Crescent Biopharma CBIO Stock Holding History

Wall Street Associates’s Portfolio CBIO Stock Details CBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$915K	Hold	1,500	–	–	0.6%	64
2016 Q3	$1.07M	Hold	1,500	–	–	0.37%	100
2016 Q2	$1.09M	Hold	1,500	–	–	0.44%	89
2016 Q1	$894K	Hold	1,500	–	–	0.37%	98
2015 Q4	$858K	Hold	1,500	–	–	0.24%	148
2015 Q3	$840K	Hold	1,500	–	–	0.16%	168
2015 Q2	$1.19M	Hold	1,500	–	–	0.11%	189
2015 Q1	$1.25M	Hold	1,500	–	–	0.12%	191
2014 Q4	$1.08M	Hold	1,500	–	–	0.1%	196
2014 Q3	$1.04M	Hold	1,500	–	–	0.11%	198
2014 Q2	$1.26M	Hold	1,500	–	–	0.11%	201
2014 Q1	$2.45M	Buy	+1,500	New	+$1.82M	0.2%	153

Other funds holding CBIO

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $22.2B AUM 58.34% 1-Year Est. Return

Wall Street Associates's CBIO Position: Q4 2016 in Review

Wall Street Associates held its Crescent Biopharma (CBIO) position steady in Q4 2016 at 1,500 shares worth $915K. The position accounts for 0.6% of the portfolio, ranked #64.

Wall Street Associates first reported a position in CBIO in Q1 2014 and has held it in 12 quarters since. The position peaked at $2.45M in Q1 2014. 50 funds tracked by Wall St. Rank hold CBIO as of Q4 2016.

Wall Street Associates held 1,500 shares of Crescent Biopharma worth $915K as of Q4 2016.
Wall Street Associates left its Crescent Biopharma share count unchanged in Q4 2016.
Crescent Biopharma made up 0.6% of Wall Street Associates's portfolio in Q4 2016, its #64 holding.
Wall Street Associates first reported a position in Crescent Biopharma in Q1 2014 and has held it in 12 quarters since.
Wall Street Associates's Crescent Biopharma position peaked at $2.45M in Q1 2014.
50 funds tracked by Wall St. Rank held Crescent Biopharma as of Q4 2016.

Based on Wall Street Associates's 13F filing for Q4 2016, filed 18 Jan 2017.